Navigation Links
Biotel Announces Profitable Second Quarter Ended December 31, 2008
Date:2/12/2009

MINNEAPOLIS, Feb. 12 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: BTEL) announced results for its second quarter ended December 31, 2008, with net earnings of $289,000, or $0.10 per diluted share, on revenues of $3,186,000. This compares to net earnings of $206,000, or $0.07 per diluted share, on revenues of $2,859,000 for the second quarter of last year. For the six months ended December 31, 2008, Biotel had net earnings of $617,000, or $0.22 per diluted share, on revenues of $6,354,000. This compares to net earnings of $376,000, or $0.13 per diluted share, on revenues of $5,610.000 for the first six months of last year.

    Highlights for the second quarter are as follows:

    * Ninth consecutive profitable quarter
    * Net income up 40.3% year over year
    * Strong gross margin of 45.9%, versus 44.7% a year ago
    * Strong balance sheet with no long-term bank debt
    * Stockholders' equity of $5,320,000, up 22.8% year over year

"We are pleased with Biotel's revenue growth, margin improvement and overall performance in the second quarter," Biotel President and CEO Steve Springrose said. "Sales of the Braemar ER920W wireless arrhythmia monitor remained strong as one of our OEM partners continued ordering product for inventory stocking. We expect sales to this customer to diminish in the second half. Sales of Braemar Holter devices, event recorders, liposuction equipment and other medical devices remained solid. Having received FDA 510(k) approval of our Fusion platform of wireless ECG monitoring products, we are beginning shipments of an evaluation version of the product this quarter, followed by a planned limited clinical release and distribution of Fusion products in our fourth quarter. Biotel serves as a development partner to medical corporations seeking new devices and clinical research services."



                               3 months ended  3 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $3,186,000      $2,859,000         11.4%
    Net Income                     $289,000        $206,000         40.3%
    Earnings Per Share, Basic         $0.10           $0.08
    Earnings Per Share, Diluted       $0.10           $0.07



                               6 months ended  6 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $6,354,000      $5,610,000         13.3%
    Net Income                     $617,000        $376,000         64.2%
    Earnings Per Share, Basic         $0.22           $0.14
    Earnings Per Share, Diluted       $0.22           $0.13

'/>"/>
SOURCE Biotel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biotel Announces Profitable Third Quarter Ended March 31, 2008
2. Biotel Announces Strong Results for the Second Quarter Ended December 31, 2007
3. Biotel Announces Strong Results for the First Quarter Ended September 30, 2007, FDA 510(k) Clearance for the Braemar ER900 Wireless Event Recorder
4. Biotel Announces Record Revenues and Strong Earnings for the Fourth Quarter and Year Ended June 30, 2007
5. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
6. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
7. Cogdell Spencer Announces Dorr as President of the Southeast Region
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
9. Terri Lynne Lokoff Child Care Foundation Announces Recipients of the 2009 Terri Lynne Lokoff/Childrens TYLENOL(R) National Child Care Teacher Awards(TM)
10. Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices
11. Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: